← Leaderboards
Michal Schnaider Beeri
Icahn School Of Medicine At Mount Sinai
$14,706,707
Attributed
$17,634,546
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,634,546 · 11
By mechanism
R01$16,248,979 · 5
R21$739,680 · 2
K01$614,648 · 1
M01$31,239 · 3
Top collaborators
- Mary Sano6 shared
- Ramit Ravona2 shared
- Aron S Buchman1 shared
- Hans-Ulrich Klein1 shared
- Jaime Uribarri1 shared
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Katherine A Ornstein$5,563,562
- Tina Neade$14,379
- Claire Kathryn Ankuda$1,607,085
- Jaime Uribarri$365,464
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposImpaired CognitionDementiaBrainCognitionDiabetes MellitusS DiseaseAffectMagnetic Resonance ImagingGlucoseCognitiveMediatingElderlyLeadDiagnosisMedical SchoolsIsraelCollaborationsHigh RiskMedical CenterHealth ServicesLinkBaseNon-Insulin-Dependent Diabetes Mellitus
Grant awards (39)
Decoding the role of the glycoproteome in Alzheimerâs disease and related disorders.$795,436
R01 · FY2025 · AG · contact PI
Systemic and dietary advanced glycation end products in type 2 diabetes-related cognitive decline and incident dementia: effects on Alzheimer's pathology and cerebrovascular disease$787,175
R01 · FY2024 · AG · contact PI
Cognitive and brain imaging correlates of apathy- components in asymptomatic middle aged individuals at high ADRD- risk$154,642
R21 · FY2024 · AG · contact PI
Systemic and dietary advanced glycation end products in type 2 diabetes-related cognitive decline and incident dementia: effects on Alzheimer's pathology and cerebrovascular disease$731,702
R01 · FY2023 · AG · contact PI
Cognitive and brain imaging correlates of apathy- components in asymptomatic middle aged individuals at high ADRD- risk$210,067
R21 · FY2023 · AG · contact PI
Systemic and dietary advanced glycation end products in type 2 diabetes-related cognitive decline and incident dementia: effects on Alzheimer's pathology and cerebrovascular disease$32,609
R01 · FY2023 · AG · contact PI
Systemic and dietary advanced glycation end products in type 2 diabetes-related cognitive decline and incident dementia: effects on Alzheimer's pathology and cerebrovascular disease$860,421
R01 · FY2022 · AG · contact PI
Systemic and dietary advanced glycation end products in type 2 diabetes-related cognitive decline and incident dementia: effects on Alzheimer's pathology and cerebrovascular disease$66,502
R01 · FY2022 · AG · contact PI
Hyperbaric oxygen therapy for cognition in diabetic elderly at high dementia risk$796,424
R01 · FY2021 · AG
Peripheral and brain levels of advanced glycation end products AGEs and incident Alzheimers disease and neuropathology$730,927
R01 · FY2021 · AG
Systemic and dietary advanced glycation end products in type 2 diabetes-related cognitive decline and incident dementia: effects on Alzheimer's pathology and cerebrovascular disease$10,902
R01 · FY2021 · AG · contact PI
Systemic and dietary advanced glycation end products in type 2 diabetes-related cognitive decline and incident dementia: effects on Alzheimer's pathology and cerebrovascular disease$854,145
R01 · FY2020 · AG · contact PI
Hyperbaric oxygen therapy for cognition in diabetic elderly at high dementia risk$796,424
R01 · FY2020 · AG · contact PI
Peripheral and brain levels of advanced glycation end products AGEs and incident Alzheimers disease and neuropathology$758,949
R01 · FY2020 · AG · contact PI
Systemic and dietary advanced glycation end products in type 2 diabetes-related cognitive decline and incident dementia: effects on Alzheimer's pathology and cerebrovascular disease$910,096
R01 · FY2019 · AG · contact PI
Hyperbaric oxygen therapy for cognition in diabetic elderly at high dementia risk$219,517
R01 · FY2019 · AG · contact PI
Peripheral and brain levels of advanced glycation end products AGEs and incident Alzheimers disease and neuropathology$770,493
R01 · FY2018 · AG · contact PI
Hyperbaric oxygen therapy for cognition in diabetic elderly at high dementia risk$611,657
R01 · FY2018 · AG · contact PI
Peripheral and brain levels of advanced glycation end products AGEs and incident Alzheimers disease and neuropathology$761,451
R01 · FY2017 · AG · contact PI
Hyperbaric oxygen therapy for cognition in diabetic elderly at high dementia risk$611,657
R01 · FY2017 · AG · contact PI
Peripheral and brain levels of advanced glycation end products AGEs and incident Alzheimers disease and neuropathology$779,023
R01 · FY2016 · AG · contact PI
Hyperbaric oxygen therapy for cognition in diabetic elderly at high dementia risk$663,782
R01 · FY2016 · AG · contact PI
Long term instability of glycemic control and hippocampal function$162,190
R21 · FY2015 · AG · contact PI
Inflammation, long-term diabetes characteristics, and cognitive decline$495,772
R01 · FY2014 · AG · contact PI
Long term instability of glycemic control and hippocampal function$212,781
R21 · FY2014 · AG · contact PI
Inflammation, long-term diabetes characteristics, and cognitive decline$598,303
R01 · FY2013 · AG · contact PI
Inflammation, long-term diabetes characteristics, and cognitive decline$670,841
R01 · FY2012 · AG · contact PI
Inflammation, long-term diabetes characteristics, and cognitive decline$78,251
R01 · FY2012 · AG · contact PI
Inflammation, long-term diabetes characteristics, and cognitive decline$556,875
R01 · FY2011 · AG · contact PI
Inflammation, long-term diabetes characteristics, and cognitive decline$628,130
R01 · FY2010 · AG · contact PI
Inflammation, long-term diabetes characteristics, and cognitive decline$671,515
R01 · FY2009 · AG · contact PI
Advanced Glycation End Products and Alzheimer's Disease$123,255
K01 · FY2009 · AG · contact PI
Advanced Glycation End Products and Alzheimer's Disease$123,095
K01 · FY2008 · AG · contact PI
EFFECTS OF GLYCOXIDATION ON COGNITION$5,137
M01 · FY2008 · RR · contact PI
Advanced Glycation End Products and Alzheimer's Disease$122,766
K01 · FY2007 · AG · contact PI
EFFECTS OF GLYCOXIDATION ON COGNITION$21,276
M01 · FY2007 · RR · contact PI
Advanced Glycation End Products and Alzheimer's Disease$122,766
K01 · FY2006 · AG · contact PI
EFFECTS OF GLYCOXIDATION ON COGNITION$4,826
M01 · FY2006 · RR · contact PI
Advanced Glycation End Products and Alzheimer's Disease$122,766
K01 · FY2005 · AG